What Imagion Biosystems’ AU$3.75m raise changes for the MagSense HER2 programme
Imagion Biosystems has converted FDA permission to proceed into funding for a Phase 1b/2 test of whether targeted MRI can improve HER2-positive breast cancer staging.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
What Bayer’s MRXperion 510(k) clearance means for high-field MRI workflow and contrast injection systems
FDA clears expanded capabilities for Bayer MRXperion MRI injector supporting scanners up to 7T. Discover what this means for imaging workflows and radiology systems.
Medical Devices & Diagnostics
Next-generation SIGNA MRI gains FDA nod, sharpening GE HealthCare’s imaging strategy
GE HealthCare secures FDA clearance for next-generation SIGNA MRI. Explore clinical impact, workflow gains, and market implications.